Fractional flow in PCI
This article was originally published in The Gray Sheet
Executive Summary
Evidence strongly suggests that angiography guided by intravascular fractional flow reserve (FFR) measurement improves outcomes in patients undergoing percutaneous coronary intervention compared to angiography alone, according to new practice guidelines from the American College of Cardiology, American Heart Association and Society for Cardiac Angiography and Interventions. The updated ACC/AHA/SCAI guidelines, published in the December issue of Circulation, elevate the level of evidence supporting FFR from Class IIa, Level B to Class IIa, Level A. FFR uses a sensor on a guidewire to measure the range of pressure across a coronary lesion to assess its severity, allowing clinicians to better decide which lesions to stent. The new guidelines cited the 2009 FAME study, showing multivessel PCI guided by FFR reduced deaths and heart attacks (1"The Gray Sheet" Oct. 5, 2009). FFR product maker Volcano (PrimeWire, FloWire and ComboWire XT) says the new guidelines should boost physician use of the procedure
You may also be interested in...
Volcano Takes Advantage Of Competitors' Trials To Tout FFR, IVUS
Intravascular imaging device-maker Volcano is talking up the results of two trials presented at the TCT conference, although it was not the primary sponsor of either of them
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.